Given that (1) neuroblastoma is an embryonal neural crest derived tumor, (2) MYCN is critical for the maintenance of embryonic stem cell-derived neural crest stem cells8 and (3) LIN28B, a known stem cell marker, acts as oncogene in neuroblastoma7, we decided to explore whether an ESC derived miRNA signature could capture a stemness phenotype in neuroblastoma cells and be applied as tool to select neuroblastoma patients with therapy resistant tumors. This evidence concerns the gene LIN28B and neoplasm.